🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluating the Addition of Hemodiafiltration to EVLP - Impact on the Regeneration of Marginal Donor Lungs

RecruitingNAAges any - anyAllMedical University of Vienna
NCT06082401 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The primary objective of the study is the evaluation of the effect of hemodiafiltration during ex vivo lung perfusion in marginal donor lungs, and its feasibility. The hypothesis of this study is that this therapy could stabilize perfusate electrolyte composition, remove toxins and waste products, normalize pH levels and prevent edema formation, thereby reconditioning marginal donor lungs for transplantation. The proposed pilot study addresses the unmet clinical needs in several aspects: a) for the first time a homeostatic device will be introduced in EVLP to reach stable perfusate composition; b) the proposed modification of the standard EVLP could lead to longer perfusion times, making elective transplantation possible and setting the base for possible ex vivo lung treatments; c) the ultimate effect of the proposed study is to increase organ availability through reconditioning of marg

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Marginal donor lungs according to the ISHLT criteria (18) * PaO2/FiO2 ratio \< 400 (with FiO2=1.0 and PEEP=5-8cmH2O) * Donor age ≥ 55 years * Smoking history ≥ 20 pack-years * Infiltrates in chest radiograph * Significant secretions in bronchoscopy * Organisms on sputum gram stain * Donor age \> 18 years Exclusion Criteria: For donor organs: * Bilateral consolidations in donor lungs * Lungs from donors with chest trauma * Lungs from drowned donors For patients receiving lung transplantation: * Inclusions in other interventional studies * Patients on the intensive care unit (ICU) prior to transplantation, with mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO) support * Re-transplantations
💊

What it tests

  • hemodiafiltration (HDF)
  • Ex vivo lung perfusion (EVLP)
📍

Where

1 site
Medical University of Vienna
Vienna, Austria
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy